- Home
- OBIO vs ZNTL Comparison
OBIO vs ZNTL Comparison
Compare OBIO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ZNTL
- Stock Information
- Founded
- OBIO 2017
- ZNTL 2014
- Country
- OBIO United States
- ZNTL United States
- Employees
- OBIO N/A
- ZNTL N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- ZNTL Health Care
- Exchange
- OBIO Nasdaq
- ZNTL Nasdaq
- Market Cap
- OBIO 118.8M
- ZNTL 105.8M
- IPO Year
- OBIO N/A
- ZNTL 2020
- Fundamental
- Price
- OBIO $2.88
- ZNTL $1.24
- Analyst Decision
- OBIO Strong Buy
- ZNTL Buy
- Analyst Count
- OBIO 5
- ZNTL 7
- Target Price
- OBIO $14.20
- ZNTL $8.60
- AVG Volume (30 Days)
- OBIO 407.3K
- ZNTL 1.4M
- Earning Date
- OBIO 08-11-2025
- ZNTL 08-08-2025
- Dividend Yield
- OBIO N/A
- ZNTL N/A
- EPS Growth
- OBIO N/A
- ZNTL N/A
- EPS
- OBIO N/A
- ZNTL N/A
- Revenue
- OBIO $2,886,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- OBIO $20.47
- ZNTL N/A
- Revenue Next Year
- OBIO $11.45
- ZNTL N/A
- P/E Ratio
- OBIO N/A
- ZNTL N/A
- Revenue Growth
- OBIO 30.23
- ZNTL N/A
- 52 Week Low
- OBIO $2.37
- ZNTL $1.01
- 52 Week High
- OBIO $8.87
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- OBIO 46.02
- ZNTL 44.51
- Support Level
- OBIO $2.60
- ZNTL $1.13
- Resistance Level
- OBIO $2.94
- ZNTL $1.39
- Average True Range (ATR)
- OBIO 0.25
- ZNTL 0.12
- MACD
- OBIO -0.05
- ZNTL -0.03
- Stochastic Oscillator
- OBIO 31.82
- ZNTL 26.83
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.